The TRIM21 therapies have been shown to remove toxic tau proteins and reduce symptoms of neurodegeneration in mice.

Immunosuppressants used in adeno-associated virus (AAV) gene therapy for monogenic disorders present an adverse effect ...

Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm’s clinical program is a LVV-based gene therapy for ...

AAVantgarde Bio (AAVantgarde), an Italy-based global biotechnology company, announced that the first subject has been dosed in the LUCE-1 trial, a Phase 1/2 open label clinical trial to assess safety ...

Delve into Vironexis' launch with a pipeline of 10 cancer drug candidates built around its AAV vectors platform.

How the hydrolytic activity of mitochondrial ATP synthase is modulated during brown adipose tissue (BAT) thermogenesis ...

Other techniques for targeting tau inside cells, such as anti-sense oligonucleotides (ASOs), have been shown to reduce tau in ...

A new study describes the use of artificial intelligence (AI) in designing a new generation of capsids, the structures that ...

Global AAV Contract Development and Manufacturing Organizations Market is valued at approximately USD 621 million in 2023 and is anticipated to grow with a healthy growth rate of more than 4.85 % over ...

Genethon , the pioneering French laboratory and leader in the research and development of gene therapies for rare diseases, announced today ...